Previous 10 | Next 10 |
Completed enrollment of Phase 2 non-small cell lung cancer trial; on track to report top line data later this year Received FDA clearance of IND application for Phase 1 trial of HS-130 in combination with HS-110 for patients with advanced solid tumors refractory t...
The FDA has signed off on Heat Biologics' (NASDAQ: HTBX ) IND application for a Phase 1 clinical trial evaluating the combination of HS-130 and HS-110 in patients with treatment-resistant solid tumors. Enrollment should start in Q4. More news on: Heat Biologics, Inc., Healthcare stocks n...
HS-130 is the first allogeneic, off-the-shelf, cell therapy approach utilizing OX40-mediated co-stimulation to enhance activation of dormant immune signals Clinical enrollment expected to commence in Q4 2019 DURHAM, NC / ACCESSWIRE / August 12, 2019 / Heat Biologics, Inc. (NAS...
DURHAM, NC / ACCESSWIRE / August 7, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing therapies designed to activate a patient’s immune system against cancer, today announced that the Company’s CEO, Jeff Wolf, and ...
Cellectar Biosciences (NASDAQ: CLRB ) initiated with Buy rating and $6 (180% upside) price target at Brookline Capital. Shares up 8% premarket. More news on: Cellectar Biosciences, Inc., Heat Biologics, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th...
DURHAM, NC / ACCESSWIRE / July 9, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient’s immune system against cancer, today announced it has completed recruitment for enrollment...
Clinicalbenefit observed in 55% of patients receiving HS-110 plus nivolumab aftercheckpoint inhibitor treatment failure HS-110 incombination with nivolumab demonstrates clinical activity in low CD8+ TIL "coldtumor" patients and PD-L1 negative tumors Theoccurrence of dermal injection sit...
DURHAM, NC / ACCESSWIRE / May 20, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it will be presenting at the 20 th Annual B. Riley FBR Institutional Investor ...
Heat Biologics (NASDAQ: HTBX ): Q1 GAAP EPS of -$0.17 beats by $0.01 . More news on: Heat Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
On track to complete enrollment of Phase 2 lung cancer trial in Q2 2019 and report additional interim data in Q4 2019 Anticipates receiving additional $6.9 million in grant funds after filing PTX-35 IND DURHAM, NC / ACCESSWIRE / May 15, 2019 / Heat Biologics, Inc. (NASDAQ: HT...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first...
DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company’s Board of ...
DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today reported that it received notice ...